NUVALENT INC-A

NUVLNASDAQ

🏆 #756 by market capUS Equity

$312.09▲ $26.53 (+8.50%)

Simulated price

1h—

24h▲ 8.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$9.79B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for NUVL.

Trading Snapshot

Day Range: $307.47 – $313.40
52-Week Range: $71.13 – $123.99
Volume: $2.33B
Avg Volume: $1.65B
Shares Outstanding: 79.1M
Next Earnings: Oct 2, 2026

Fundamentals Snapshot

Annual Revenue: $3.63B
Last Q Revenue: $824M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-6.05
Dividend Yield: —

Why Investors Own NUVL

✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3.63B▲ +18.5% YoY

Gross Margin (TTM)

35.6%▲ +3.1% YoY

Operating Income (TTM)

$1.13B▲ +18.5% YoY

Free Cash Flow (TTM)

$733M▲ +18.5% YoY

About NUVALENT INC-A

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

🦦